VANCOUVER, BC, Jan. 2, 2024 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioural health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, will release its financial results for the quarter ended November 30, 2023, after market close on Tuesday, January 15, 2024.
Interested parties are invited to participate in the Company's Q1 2024 results conference call and webcast occurring on the same day at 5:30 p.m. Eastern time / 2:30 p.m. Pacific time. During the call, Numinus executives will review the Company's performance and recent initiatives.
A question-and-answer session will follow management's prepared remarks. At this time, the operator will provide instructions for qualified equity analysts to submit questions. Investors are invited to submit questions by email to This email address is being protected from spambots. You need JavaScript enabled to view it.. A selection of questions will be answered by management on the call, and all emailed questions will be responded to by email.
To listen to the live webcast, please register at:
https://events.q4inc.com/attendee/589132840
The webcast will also be archived on the Events and Presentations page of Numinus' Investor Relations website: https://www.investors.numinus.com/events-and-presentations/
To participate in the live conference call, please use the following dial-in information:
To avoid any delays in joining the call, please dial in at least five minutes prior to the call start time. If prompted, please provide conference passcode 3547386.
A replay of the conference call can also be accessed after 8:30 p.m. Eastern time / 5:30 p.m. Pacific time on January 15, 2024, at 1-800-770-2030 or 1-647-362-9199 (using passcode 3547386). The replay will be available until January 29, 2024.
Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model – including psychedelic research and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.
Learn more at www.numinus.com and follow us on LinkedIn, Facebook, Twitter, and Instagram.
| Last Trade: | US$0.04 |
| Daily Change: | -0.0041 -10.12 |
| Daily Volume: | 7,000 |
| Market Cap: | US$11.670M |
May 30, 2024 April 17, 2024 | |
Surf Air Mobility is a regional air mobility platform expanding the category of regional air travel to reinvent flying through the power of electrification. In an effort to substantially reduce the cost and environmental impact of...
CLICK TO LEARN MORE
Else Nutrition is changing the face of early childhood nutrition with clean, sustainable, plant-based products. The company has developed the world’s first whole plant-based infant formula that is targeting the $100+ billion global...
CLICK TO LEARN MORE